
aug pm et
summari develop proprietari product use cardiologist physician heart surgeon
angioplasti heart surgeri procedur
nm price-to-earnings oper ep
risk assess reflect lead posit
vital market -- develop proprietari product
design enabl heart rest heal recov
improv blood flow coronari arteri howev
note highli innov competit marketplac
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
fy sale grew
beat expect growth
look fy fy sale rise
respect driven
continu robust sale impella
heart pump product estim
market penetr rate still low
estim patient us
alon see increas patient usag aid
larger instal base expand
intern sale physician becom
awar often lifesav devic
look fy fy oper margin
rise respect
fy invest expans
continu pay octob
announc first patient treat
impella heart pump japan accord
second largest medic
devic market world although sale
japan low fy see vigor
growth opportun japan
expect add million japan revenu
fy ultim hospit
countri
forecast fy ep grow
fy
see one fastest grow
growth averag quarter
end march show littl sign
deceler revenu grew
latest quarter june germani
japan import growth driver
wide accept nation like
lead rapid adopt surround region
view share histor
trade eye-pop premium
leadership posit transform
technolog rapid sale earn
growth mention march
earn call explor altern use
technolog could yield result
year stock expens trade
forward earn howev
exuber long-term opportun could
support share near term
risk target price recommend
includ potenti product liabil lawsuit
threat potenti competitor
particularli newer market
target base
above-p ep
estim line
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead provid temporari mechan circulatori support
devic develop manufactur market proprietari product design enabl
heart rest heal recov improv blood flow coronari arteri end-organ and/or
temporarili perform pump function heart compani product use cardiac
catheter lab intervent cardiologist electrophysiolog lab hybrid lab heart
surgeri suit heart surgeon physician might use devic patient need
hemodynam support angioplasti heart surgeri procedur
primari product impella product portfolio includ impella impella cp impella
rp impella ld impella product pipelin includ impella impella ecp impella
btr product servic revenu near futur impella devic
work expand usag awar impella product
one recent fda-approv product impella rp heart pump indic
provid temporari right ventricular support day certain patient develop acut right
heart failur decompens follow left ventricular assist devic implant myocardi infarct
heart transplant open-heart surgeri impella rp heart pump percutan temporari
ventricular support devic fda-approv safe effect right heart failur
recent develop includ april fda approv impella cp smartassist
optic sensor februari receiv two expand pre-market approv pma fda
impella heart pump first expand approv use impella cp ld heart
pump patient cardiogen shock associ cardiomyopathi second expand pma
approv use impella impella cp heart pump elect high-risk
support appropri patient sever coronari arteri diseas complex anatomi extens
comorbid without depress eject fraction
market profil accord aha heart diseas stroke statist updat report
coronari heart diseas caus approxim one everi seven death
condit coronari arteri caus reduc blood flow insuffici oxygen deliveri
affect portion heart lead acut myocardi infarct ami commonli known heart
attack may lead heart failur condit heart unabl pump enough blood
bodi major organ
competit among provid treatment fail heart intens subject rapid
technolog chang evolv industri requir standard present futur
product could render obsolet uneconom result technolog advanc one
present futur competitor therapi includ drug therapi must
continu develop commerci new product technolog remain competit
cardiovascular medic technolog industri believ compet primarili basi
clinic superior support extens data innov featur enhanc patient benefit
product perform eas use reliabl
heart replac devic research effort canada europ japan
addit sever compani includ
sever early-stag compani develop heart assist product includ implant left
ventricular assist devic miniatur rotari ventricular assist devic directli indirectli
compet product
financi trend revenu grew million fy million fy
five-year cumul annual growth rate compound-annual-growth-rate revenu -- one highest growth rate
medic equip suppli industri five-year ep compound-annual-growth-rate even higher ep
fy vs fy fy histor debt cash
flow grow free cash flow defin cash flow oper less capit
expenditur grew million million fy million fy think
financi sound posit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc juli technic indic
neutral
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
stop medicaid expans senat
fail multipl time gather
suffici number vote pass variou
repeal replac bill howev republican
success elimin individu
mandat passag tcja
decemb see develop
neg health care equip
compani fewer insur patient
futur like lead fewer procedur
expect hospit largest
consum medic equip
advers impact could pressur
sale medic equip compani
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
sub-index increas vs rise
 composit index year
date june health
increas composit index
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
addit sub-industri mani product
area histor
use non-elect procedur
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
expans acquisit speed
new product come market
increas recent year
success effort food drug
administr fda reduc approv
time medic devic time
see price pressur incess head wind
medic equip compani although
hospit saw boost cash tcja
tax cut job act think
hospit cautiou capit
budget amid on-going shift value-bas
care loom roll-off
medic devic tax sought rais
total billion year took
effect mani compani implement
cost optim measur respons
medic devic excis tax suspend
sinc begin
suspend till end compani
health care equip sub-industri stand
benefit medic devic tax repeal
develop
question opinion
recent republican administr
 difficulti attempt
repeal afford act
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
impella impella cp heart pump rose hospit
guid fy sale growth oper margin rang
initi fy ep estim see acceler oversea
sale particularli germani japan recent approv /jeffrey loo cfa
analyst research note compani news
lift target price
above-p ep estim multipl
near middl abmd five-year rang jun-q ep
vs lower estim rais
ep ep jun-q sale
increas million compris growth impella heart
pump revenu million growth outsid impella revenu
million continu anticip industry-lead revenu growth
especi abroad howev think stock alreadi
rais target above-p
fy ep estim multipl close
averag three-year rang mar-q ep vs
higher estim rais fy ep
initi fy ep mar-q sale increas
million us impella heart pump product revenu rose
million increas patient util outsid us impella
revenu grew million primarili driven increas
german revenu million although provid specif
number compani highlight exceed fy revenu goal
japan also expect add million japan revenu fy
encourag compani explor new use technolog
next year howev time wari lofti
rais target price well peer
ratio base fy march ep estim
rais fy ep estim dec-q ep vs
ahead estim sale rose sale
intern sale primarili germani japan smaller base
anticip continu robust growth impella heart pump client base
grow intern market still earli stage see
rais target price well-above-p
ratio base forward ep estim
anticip robust growth next sever year hospit base
expand sept-q ep vs ahead estim sale
rose driven rise impella heart pump sale sale
germani sale albeit small base octob announc
first patient japan treat impella heart pump anticip
japan becom import growth driver /jeffrey loo cfa
et cfra keep hold opinion share inc
rais target well-above-p
ratio base fy ep estim
faster sale earn growth jun-q ep vs ahead
estim sale rose impella heart pump aid
rise germani albeit small base instal hospit base
impella heart pump rose hospit instal base
impella cp heart pump rose encourag
metric see acceler sale germani japan /jeffrey loo cfa
et cfra keep hold opinion share inc
keep target price peer
ratio base fy ep estim faster growth -q
ep vs ahead estim sale rose
impella heart pump sale abmd instal hospit base
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
